This promotional symposium is funded and organised by Ipsen, for healthcare professionals only.
This video presents the satellite symposium hosted by Ipsen at the 56th Annual Meeting of the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) 2024, Milan, Italy.
Progressive familial intrahepatic cholestasis (PFIC) is a group of rare but serious cholestatic diseases characterised by abnormal bile secretion.1 This symposium describes how the introduction of non-surgical biliary diversion treatment may alter the standard of care for PFIC.
Symposium agenda:
- Welcome
- Prolonging native liver survival: is this the ultimate goal in PFIC treatment?
- Improving outcomes in the real world across PFIC types
- A new standard of care for patients with PFIC
This promotional symposium is funded and organised by Ipsen, for healthcare professionals only. Prescribing information and adverse events reporting details will be available at the end of the on-demand recording. This session is not included in the main event CME/CPD credit.
Prescribing Information: Click here for prescribing information.
Adverse event reporting:
| ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions to [email protected] and via the national reporting system as described in section 4.8 of the product prescribing information. |
Reference
- Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol. 2014;4(1):25-36.
Job code: BYL-ALL-000771
Date of Prep: May 2024
